McKesson Corporation has announced a strategic joint venture with HCA Healthcare, aimed at enhancing cancer care and access to oncology research. McKesson will hold a 51% stake and maintain operational control, merging its US Oncology Research with HCA’s Sarah Cannon Research Institute. The partnership comes on the heels of McKesson's robust financial performance, featuring a 64.5% gain over the past year, and follows its recent acquisition of SCRI’s personalized medicine platform, Genospace.
“McKesson Corporation · is joining · research forces”
“HCA Healthcare Inc. and McKesson Corporation · have agreed to form · a joint venture”
“McKesson · will own · 51% of the joint venture”
“McKesson · will possess · operating control”
“McKesson Corporation · announced an agreement to form · a joint venture with HCA Healthcare, Inc. · true”
“McKesson · will own · the majority stake in the joint venture · true”
“McKesson · confirmed that it will acquire · SCRI’s personalized medicine platform, Genospace · true”
“McKesson · has gained · 64.5% in the past year · true”
“McKesson Corporation · announced · agreement to form a joint venture · combining McKesson’s US Oncology Research and HCA Healthcare’s Sarah Cannon Research Institute”
“McKesson · will own · 51% of the joint venture · and have operating control”
“McKesson · will acquire · Genospace · SCRI’s personalized medicine platform”
“McKesson Corporation · announced an agreement to form · a joint venture with HCA Healthcare · recently”